feedback

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: April 13, 2020
Expires: April 13, 2021
60 minutes to complete

Accredited By

Target Audience

The target audiences are headache specialists and PCPs. Other healthcare professionals who treat patients with migraine, including general neurologists, physician assistants, nurse practitioners, nurses, and pharmacists, may benefit from participation.

Learning Objectives

Upon completion of this activity, participants should be able to

  • Apply concepts in migraine pathophysiology and therapeutic mechanism of action (MOA) to treatment discussions
  • Develop treatment plans in line with current standards of practice and guidelines for the management of migraine and episodic cluster headache (eCH)
  • Effectively communicate with patients using shared decision making (SDM) to diagnose and treat headache disorders
  • Analyze safety and efficacy profiles for new and emerging therapies in acute and preventive treatment of migraine and eCH
  • Discuss burden of migraine and eCH and impact to quality of life (QoL)

Activity Description

Delve deep into the scientific advances in migraine and episodic cluster headache (eCH) through a mixed reality experience as faculty demonstrate the intricacies of acute and preventive treatments with a HoloLens device. This CME presentation features a case series and faculty discussion to strengthen expertise in treating migraine and eCH to alleviate patient burden and improve their quality of life.

Statement of Educational Need

The burst of mechanism-specific treatments for migraine prevention has transformed lives of patients and may do the same for those with episodic cluster headache. New challenges face healthcare professionals, managing the use of therapies antagonizing the calcitonin gene-related peptide system and readying for the next evolution of acute migraine treatments, including ditans and gepants.

Agenda

  • Welcome and Session Overview
  • Pathophysiology and Mechanism of Action Depicted in Mixed Reality
  • Cases in Episodic Migraine and Episodic Cluster Headache
  • Question and Answer Session
  • Adjournment

Faculty

Merle L. Diamond, MD
President and Managing Director,
Diamond Headache Clinic
Chicago, Illinois


Stewart J. Tepper, MD
Professor of Neurology,
Geisel School of Medicine at Dartmouth
Director, Dartmouth Headache Center
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire


Wade M. Cooper, DO
Associate Professor of Neurology,
Michigan Medicine
Director,
Headache and Neuropathic Pain Program
University of Michigan
Ann Arbor, Michigan


Conflict of Interest Policy/Disclosure Statement

Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below as they were at the time of recording.

*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.

The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:

  • Planner (Forefront Collaborative): Sydney Pate, MS
  • Planner (Shared Decision Making): Sarina Schrager, MD

The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:

  • Planner (SDM Table)**: Jessica Ailani, MD, has consulted for Allergan, Alder Biopharmaceuticals, Amgen, Lilly, ElectroCore, and Promius; she has participated in a speaker’s bureau for Allergan, Amgen, Avanir Pharmaceuticals, Lilly, ElectroCore, Promius, and Teva Pharmaceutical Industries; Dr. Ailani has participated in an advisory board for Biohaven, Impel, and Satsuma Pharmaceuticals; she has contracted research from Amgen
  • Planner (HoloLens)**: Rami Burstein, PhD, has received a consulting fee for Alder Biopharmaceuticals, Allergan, Dr. Reddy’s, Lilly, Novartis, and Teva Pharmaceutical Industries; he has participated in an advisory board for Alder Biopharmaceuticals, Allergan, Dr. Reddy’s, Novartis, Revance, and Teva Pharmaceutical Industries; Dr. Burstein has contracted research from Allergan, Dr. Reddy’s, and Teva Pharmaceutical Industries
  • Planner (Forefront Collaborative): Lily Zurkovsky, PhD, has personal stock in Teva Pharmaceutical Industries
  • Presenter: Merle Diamond, MD, has consulted for Alder BioPharmacuticals, Amgen, Eli Lilly & Co., Promius Pharma, Teva Pharmaceutical Industries Ltd.; she has participated in a speaker’s bureau for Amgen, Assertio Therapeutics, Eli Lilly & Co., Supernus Pharmaceuticals, and Teva Pharmaceutical Industries Ltd.; Dr. Diamond has participated in an advisory board for Alder BioPharmacuticals, Amgen, Assertio Therapeutics, Eli Lilly & Co., Promius Pharma, Supernus Pharmaceuticals, Teva Pharmaceutical Industries Ltd., and Upsher-Smith Laboratories
  • Presenter: Wade Cooper, DO, has consulted and participated in an advisory board for Alder, Amgen, Eli Lilly, Lundberg, and Teva
  • Presenter: Stewart Tepper, MD, has grants for research with no personal compensation from Alder, Allergan, Amgen, Dr. Reddy’s, ElectroCore, Eli Lilly, eNeura, Neurolief, Novartis, Scion Neurostim, Teva, and Zosano; he has consulted for Acorda, Alder, Alexsa, Align Strategies, Allergan, Alphasights, Amgen, Aperture Venture Partners, Aralez Pharmaceuticals Canada, Axsome Therapeutics, Becker Pharmaceutical Consulting, BioDelivery Sciences International, Biohaven, Charleston Labs, Currax, Decision Resources, DeepBench, Dr. Reddy’s, ElectroCore, Eli Lilly, eNeura, Equinox, ExpertConnect, GLG, GSK, Guidepoint Global, Impel, M3 Global Research, Magellan Rx Management, Marcia Berenson Connected Research and Consulting, Medicxi, Navigant Consulting, Neurolief, Nordic BioTech, Novartis, Pfizer, Reckner Healthcare, Relevale, Revance, Satsuma, Scion Neurostim, Slingshot Insights, Sorrento, Spherix Global Insights, Sudler and Hennessey, Synapse Medical Communications, Teva, Theranica, Thought Leader Select, Trinity Partners, XOC, and Zosano; Dr. Tepper participated on an advisory board for Acorda, Alder/Lundbeck, Allergan, Amgen, Aralez Pharmaceuticals Canada, Biohaven, Eli Lilly, GSK, Novartis, Pfizer, Satsuma, Teva, Theranica, XOC, and Zosano; Dr. Tepper has stock options in Percept; he receives salary from Dartmouth-Hitchcock Medical Center and the American Headache Society

**Disclosed at the time of original work.

Accreditation Statement

Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Forefront Collaborative designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

Disclaimer Statement/Disclosure of Unlabeled Use

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative and Lilly.

The content of this activity was independently peer reviewed by two reviewers and a patient with migraine. The reviewers of this activity have no relevant financial relationships to disclose.

This continuing medical education activity will include reference(s) to unlabeled or unapproved uses of drugs or devices.

Contact Information for Questions About the Activity

Thank you for your participation! We value your opinion. If you have any feedback or questions about this educational activity, please contact info@forefrontcollab.com.

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Start Activity

Select your specialty

You must select a specialty

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.